MetaCap

Vaxcyte Inc. (PCVX)

NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

55.39-2.97 (-5.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PCVX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$8.05
52-week range
42.40 – 90.75
Day range
55.27 – 58.48
Volume / Avg
1.91M / 2.19M
Beta
—

52-week range

$42.40$90.75

PCVX stock today

Shares of Vaxcyte (PCVX) finished lower on Nov 20 at $55.39, a drop of 5.09% or $2.97 per share, versus the S&P 500's 3.70% decline. Shares are 39.0% below their 52-week high of $90.75, set on Oct 5, 2026 and 30.6% above the 52-week low of $42.40, in the middle of the past year's range. PCVX is up 20.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 15.9%.

Vaxcyte has posted a net loss over the last twelve months (EPS of -$8.05), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Vaxcyte

Company profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Grant E. Pickering M.B.A.
Headquarters
San Carlos, CA
Employees
507
IPO year
2020

Financial highlights

Full financials

Vaxcyte reported a net loss of $766.6 million, compared with a loss of $463.9 million a year earlier. Diluted earnings per share came in at -$5.63.

Vaxcyte annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-766.63M$-463.93M$-402.27M$-223.49M$-100.08M
EPS (diluted)$-5.63$-3.80$-4.14$-3.44$-1.93

Analyst forecast

Forecast

Consensus (11 analysts)

none

Avg. price target

$116.40+110.15%

  • Strong buy 1
  • Buy 9
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $75.00High $163.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-1.99 vs $-1.84
Surprise
-8.15%

PCVX news

All PCVX news

Vaxcyte peers

Health Care sector
PCVX peer companies
CompanyPrice% ChgMarket capCompare
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs PCVX
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs PCVX
QGENQiagen N.V.49.30-0.66%$10.18Bvs PCVX
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs PCVX
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs PCVX
RGENRepligen Corporation163.81-3.81%$10.47Bvs PCVX
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs PCVX
IMVTImmunovant Inc.31.77-2.31%$6.57Bvs PCVX

Indexes, lists and sector

Vaxcyte stock FAQ

What is Vaxcyte's stock price today?

PCVX last traded at $55.39 as of Nov 20, 4:00 PM EST, down 5.09% on the day. Prices are delayed at least 15 minutes.

Who is Vaxcyte's CEO?

Mr. Grant E. Pickering M.B.A. is the chief executive officer of Vaxcyte Inc., which has about 507 employees.

What is the PCVX 52-week high?

The 52-week high for PCVX is $90.75 and the 52-week low is $42.40. The stock is currently 39.0% below its high.

Compare PCVX